Börse:
1,215€
-0,41%
Echtzeit-Aktienkurs Athersys
Bid:
1,200€
Ask:
1,230€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 175,32 Mio. EUR (144,29 Mio. x 1,215€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | 8,51 | 6,07 | 40,00 | 7,22 |
| KGV | - | - | - | - |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der Athersys Aktie
Börsenkurse Athersys
| Dollar Indikation | 1,330$ | 0 | 1,360$ | 0 | 1,345$ | -1,82% |
| Börse Stuttgart | 1,180€ | 7500 | 1,260€ | 7500 | 1,220€ | 2,52% |
| Tradegate | 1,200€ | 5900 | 1,230€ | 5700 | 1,215€ | -0,41% |
| Euro Indikation | 1,200€ | 0 | 1,230€ | 0 | 1,215€ | -0,41% |
| Lang & Schwarz | 1,210€ | 20243 | 1,230€ | 20243 | 1,220€ | -1,21% |
Fundamentaldaten der Athersys Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 24,29 Mio. | -24,28 Mio. | -24,28 Mio. | -0,18 | 0,00% | - | 7,22 |
| 2017 | 3,71 Mio. | -32,24 Mio. | -32,24 Mio. | -0,29 | 0,00% | - | 40,00 |
| 2016 | 17,35 Mio. | -15,37 Mio. | -15,34 Mio. | -0,18 | 0,00% | - | 6,07 |
| 2015 | 11,95 Mio. | -16,46 Mio. | -16,42 Mio. | -0,20 | 0,00% | - | 8,51 |
| 2014 | 1,62 Mio. | -22,34 Mio. | -22,08 Mio. | -0,31 | 0,00% | - | 58,17 |
| 2013 | 2,44 Mio. | -30,74 Mio. | -30,74 Mio. | -0,53 | 0,00% | - | 35,23 |
| 2012 | 8,71 Mio. | -14,74 Mio. | -14,74 Mio. | -0,45 | 0,00% | - | 7,40 |
| 2011 | 10,34 Mio. | -13,75 Mio. | -13,75 Mio. | -0,59 | 0,00% | - | 2,88 |
| 2010 | 8,94 Mio. | -11,38 Mio. | -11,38 Mio. | -0,60 | 0,00% | - | 2,57 |
| 2009 | 2,16 Mio. | -15,37 Mio. | -15,37 Mio. | -0,81 | 0,00% | - | 10,65 |
Profil der Athersys Aktie
Athersys, Inc. is a biotechnology company, which focuses in the field of regenerative medicine and engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen